NRIX

Nurix Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · nurixtx.com

$16.93

Mkt Cap $1.5B

52w Low $8.20 61.1% of range 52w High $22.50

50d MA $15.86 200d MA $14.10

P/E (TTM) -5.5x

EV/EBITDA -5.2x

P/B 2.7x

Debt/Equity 0.1x

ROE -61.4%

P/FCF -5.6x

RSI (14) —

ATR (14) —

Beta 1.98

50d MA $15.86

200d MA $14.10

Avg Volume 1.1M

About

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for th…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 8, 2026	AMC	-0.76	-0.79	-3.9%	15.60	+0.0%	+4.1%	+2.8%	+2.0%	+4.5%	+8.8%	—	—
Jan 28, 2026	AMC	-0.84	-0.82	+2.4%	17.87	+2.1%	-1.6%	-7.6%	-4.4%	-6.0%	-7.4%	-10.6%	—
Oct 9, 2025	AMC	-0.84	-1.03	-22.6%	10.86	-10.6%	-10.1%	-10.5%	-15.5%	-4.7%	-7.6%	+12.8%	—
Jul 9, 2025	AMC	-0.71	-0.52	+26.8%	13.18	+9.9%	-3.9%	-5.6%	-3.7%	-7.8%	-5.8%	-25.3%	—
Apr 8, 2025	AMC	-0.72	-0.67	+6.9%	9.26	-1.0%	+3.7%	-4.9%	-1.3%	+6.4%	+6.0%	+4.1%	—
Jan 28, 2025	AMC	-0.67	-0.75	-11.9%	19.56	+0.0%	+0.5%	+2.4%	+0.8%	-3.1%	-5.0%	-23.3%	—
Oct 11, 2024	AMC	-0.67	-0.67	+0.0%	23.63	-0.5%	+6.5%	+5.2%	+9.2%	+4.6%	+6.0%	+19.1%	—
Jul 11, 2024	AMC	-0.66	-0.71	-7.6%	22.03	-0.8%	+8.1%	+3.0%	+3.5%	-1.2%	-4.0%	-3.7%	—
Apr 10, 2024	AMC	-0.80	-0.76	+5.0%	15.69	+8.9%	+9.7%	+6.7%	-1.5%	-6.6%	-10.3%	-13.9%	—
Feb 15, 2024	AMC	-0.51	-0.77	-51.0%	9.85	-6.1%	+0.2%	+2.4%	+1.9%	+7.1%	+3.6%	+30.4%	—
Oct 12, 2023	AMC	-0.69	-0.68	+1.4%	6.23	+2.6%	+2.2%	+2.9%	-2.4%	-15.2%	-23.5%	-15.6%	—
Jul 13, 2023	AMC	-0.63	-0.45	+28.6%	10.08	+7.5%	-3.2%	-2.2%	-3.3%	-3.5%	-4.0%	-10.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.68	$16.52	-1.0%	-1.1%	+2.4%	-0.4%	+0.1%	+0.8%
Apr 23	Needham	Maintains	Buy → Buy	—	$16.63	$16.69	+0.4%	-0.4%	+0.3%	-0.8%	+2.7%	-0.1%
Apr 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.24	$16.30	+0.4%	-1.3%	-2.0%	+0.4%	+4.5%	+2.8%
Apr 9	Wells Fargo	Maintains	Overweight → Overweight	—	$15.60	$15.60	+0.0%	+4.1%	+2.8%	+2.0%	+4.5%	+8.8%
Apr 8	Needham	Maintains	Buy → Buy	—	$16.35	$16.57	+1.3%	-4.6%	-0.7%	-2.0%	-2.7%	-0.3%
Mar 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.69	$14.52	-1.2%	-1.7%	+5.1%	+5.7%	+0.5%	-0.1%
Jan 29	Wells Fargo	Maintains	Overweight → Overweight	—	$17.87	$18.25	+2.1%	-1.6%	-7.6%	-4.4%	-6.0%	-7.4%
Jan 29	BTIG	Maintains	Buy → Buy	—	$17.87	$18.25	+2.1%	-1.6%	-7.6%	-4.4%	-6.0%	-7.4%
Jan 29	Stifel	Maintains	Buy → Buy	—	$17.87	$18.25	+2.1%	-1.6%	-7.6%	-4.4%	-6.0%	-7.4%
Jan 29	Needham	Maintains	Buy → Buy	—	$17.87	$18.25	+2.1%	-1.6%	-7.6%	-4.4%	-6.0%	-7.4%
Jan 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.87	$18.25	+2.1%	-1.6%	-7.6%	-4.4%	-6.0%	-7.4%
Jan 29	RBC Capital	Maintains	Outperform → Outperform	—	$17.87	$18.25	+2.1%	-1.6%	-7.6%	-4.4%	-6.0%	-7.4%
Jan 29	Piper Sandler	Maintains	Overweight → Overweight	—	$17.87	$18.25	+2.1%	-1.6%	-7.6%	-4.4%	-6.0%	-7.4%
Jan 8	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$18.49	$19.86	+7.4%	+0.8%	+4.4%	-0.6%	+2.4%	+3.0%
Dec 16	Wells Fargo	Maintains	Overweight → Overweight	—	$19.01	$19.06	+0.3%	-0.9%	-4.2%	-5.3%	-2.6%	+1.7%
Dec 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.55	$20.07	+2.7%	+0.3%	-2.5%	-2.5%	-2.8%	-3.6%
Dec 10	Mizuho	Maintains	Outperform → Outperform	—	$19.55	$20.07	+2.7%	+0.3%	-2.5%	-2.5%	-2.8%	-3.6%
Dec 9	BTIG	Maintains	Buy → Buy	—	$21.47	$21.43	-0.2%	-8.9%	-8.7%	-11.2%	-11.2%	-11.5%
Dec 8	Needham	Maintains	Buy → Buy	—	$18.09	$21.43	+18.5%	+18.7%	+8.1%	+8.4%	+5.4%	+5.4%
Nov 4	BTIG	Maintains	Buy → Buy	—	$12.62	$12.30	-2.5%	-2.9%	-1.3%	-0.8%	-2.5%	-2.9%
Nov 4	Needham	Maintains	Buy → Buy	—	$12.62	$12.30	-2.5%	-2.9%	-1.3%	-0.8%	-2.5%	-2.9%
Oct 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.09	$11.21	+1.1%	+8.0%	+7.3%	+5.5%	+15.2%	+16.7%
Oct 23	Wells Fargo	Maintains	Overweight → Overweight	—	$10.63	$10.54	-0.8%	-2.2%	+4.3%	+12.7%	+11.9%	+10.1%
Oct 23	BTIG	Maintains	Buy → Buy	—	$10.63	$10.54	-0.8%	-2.2%	+4.3%	+12.7%	+11.9%	+10.1%
Oct 22	Needham	Maintains	Buy → Buy	—	$10.42	$11.69	+12.2%	+2.0%	-0.2%	+6.4%	+15.0%	+14.2%
Oct 20	Needham	Maintains	Buy → Buy	—	$9.84	$10.09	+2.5%	+5.6%	+5.9%	+8.0%	+5.7%	+12.7%
Oct 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.84	$10.09	+2.5%	+5.6%	+5.9%	+8.0%	+5.7%	+12.7%
Oct 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.72	$9.43	-3.0%	-5.6%	+6.5%	+3.2%	+1.2%	+6.9%
Oct 14	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$9.72	$9.43	-3.0%	-5.6%	+6.5%	+3.2%	+1.2%	+6.9%
Oct 10	Oppenheimer	Maintains	Outperform → Outperform	—	$10.86	$9.71	-10.6%	-10.1%	-10.5%	-15.5%	-4.7%	-7.6%
Oct 10	Piper Sandler	Maintains	Overweight → Overweight	—	$10.86	$9.71	-10.6%	-10.1%	-10.5%	-15.5%	-4.7%	-7.6%
Jul 31	Oppenheimer	Maintains	Outperform → Outperform	—	$11.88	$11.55	-2.8%	-5.2%	-7.1%	-5.1%	-4.8%	-12.0%
Jul 15	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$12.69	$12.68	-0.1%	-4.3%	-2.1%	-4.7%	-11.7%	-11.3%
Jul 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.44	$12.25	-1.5%	+2.0%	-2.3%	-0.2%	-2.8%	-9.9%
Jul 10	UBS	Maintains	Buy → Buy	—	$13.18	$14.48	+9.9%	-3.9%	-5.6%	-3.7%	-7.8%	-5.8%
Jul 10	Stephens & Co.	Maintains	Overweight → Overweight	—	$13.18	$14.48	+9.9%	-3.9%	-5.6%	-3.7%	-7.8%	-5.8%
Jul 10	Oppenheimer	Maintains	Outperform → Outperform	—	$13.18	$14.48	+9.9%	-3.9%	-5.6%	-3.7%	-7.8%	-5.8%
Apr 29	Needham	Maintains	Buy → Buy	—	$11.47	$11.54	+0.6%	-0.3%	+0.5%	-2.7%	-1.7%	-4.6%
Apr 9	Needham	Maintains	Buy → Buy	—	$9.26	$9.17	-1.0%	+3.7%	-4.9%	-1.3%	+6.4%	+6.0%
Apr 9	Wells Fargo	Maintains	Overweight → Overweight	—	$9.26	$9.17	-1.0%	+3.7%	-4.9%	-1.3%	+6.4%	+6.0%
Apr 9	Stifel	Maintains	Buy → Buy	—	$9.26	$9.17	-1.0%	+3.7%	-4.9%	-1.3%	+6.4%	+6.0%
Apr 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.47	$10.30	-1.6%	+8.7%	+0.4%	-7.4%	-7.2%	-11.6%
Feb 3	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$19.71	$19.60	-0.6%	-3.9%	-5.7%	-2.6%	-3.4%	-4.2%
Jan 29	Needham	Maintains	Buy → Buy	—	$19.56	$19.56	+0.0%	+0.5%	+2.4%	+0.8%	-3.1%	-5.0%
Jan 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.56	$19.56	+0.0%	+0.5%	+2.4%	+0.8%	-3.1%	-5.0%
Jan 29	RBC Capital	Maintains	Outperform → Outperform	—	$19.56	$19.56	+0.0%	+0.5%	+2.4%	+0.8%	-3.1%	-5.0%
Jan 29	Stifel	Maintains	Buy → Buy	—	$19.56	$19.56	+0.0%	+0.5%	+2.4%	+0.8%	-3.1%	-5.0%
Jan 29	JP Morgan	Maintains	Overweight → Overweight	—	$19.56	$19.56	+0.0%	+0.5%	+2.4%	+0.8%	-3.1%	-5.0%
Jan 21	Stephens & Co.	Maintains	Overweight → Overweight	—	$19.14	$19.42	+1.5%	+2.4%	+2.8%	+4.3%	+4.1%	+3.5%
Dec 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.06	$22.95	+4.0%	-3.4%	-6.8%	-8.1%	-5.7%	-4.0%

Recent Filings

8-K

Unknown — 8-K Filing

Nurix's advancement toward regulatory approval of bexobrutideg and multiple 2026 catalysts could significantly de-risk the company and drive stock appreciation if clinical milestones succeed.

Apr 8

8-K

Nurix Therapeutics, Inc. -- 8-K Filing

Nurix Therapeutics received legal counsel confirmation that its share offering complies with securities registration requirements across jurisdictions.

Mar 6

Data updated apr 26, 2026 3:44pm · Source: massive.com